At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
Aliskiren +3 moredrug
Likely dose
Aliskiren 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Eight-week, Randomized, Double-blind, Parallel-group, Pilot Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg in Comparison With Valsartan 320 mg in Patients With Mild to Moderate Hypertension During Exercise After a Missed Dose
In Brief
A Phase 2 clinical trial evaluating Aliskiren, Valsartan, and 2 other interventions for Hypertension. Completed, enrolled 68 participants across 8 sites in 4 countries.
Detailed Summary
This study compared the blunting effect of aliskiren and valsartan monotherapies on exercise-induced rises in systolic blood pressure in patients with mild to moderate essential hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesCzechia, Hungary, Singapore, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartFeb 2009
Primary CompletionOct 2009
TodayJul 2026
First PostedJan 9, 2009
Enrollment StartFeb 1, 2009
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.5 years ago
Interventions
Aliskirendrug
Aliskiren was supplied in 150 mg tablets.
Valsartandrug
Valsartan was supplied in 160 mg capsules.
Placebo to aliskirendrug
Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.
Placebo to valsartandrug
Placebo to valsartan was supplied in capsules matching valsartan 160 mg.